Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OncoCyte Corp OCX

Healthcare Biotechnology
Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict... see more

Recent & Breaking News (NDAQ:OCX)

Oncocyte Begins Manufacturing Transplant Blood Test

GlobeNewswire June 27, 2023

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Newsfile June 1, 2023

Oncocyte Reports First Quarter 2023 Financial Results

GlobeNewswire May 11, 2023

Oncocyte To Announce First Quarter 2023 Financial Results

GlobeNewswire April 27, 2023

Oncocyte Presents New Data at AACR

GlobeNewswire April 18, 2023

Oncocyte Announces Reduction in Force

GlobeNewswire April 12, 2023

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

GlobeNewswire April 7, 2023

Oncocyte Pricing of $13.86 Million Public Offering of Common Stock

GlobeNewswire April 3, 2023

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

GlobeNewswire March 31, 2023

Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

GlobeNewswire March 29, 2023

Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire March 15, 2023

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

GlobeNewswire March 2, 2023

Oncocyte Completes Razor Genomics Transaction

GlobeNewswire February 22, 2023

Oncocyte Announces Initiatives to Focus Corporate Strategy

GlobeNewswire December 16, 2022

Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors

GlobeNewswire November 30, 2022

Oncocyte Announces Executive Leadership Changes

GlobeNewswire November 30, 2022

Oncocyte Reports Third Quarter 2022 Financial Results

GlobeNewswire November 10, 2022

Oncocyte to Announce Third Quarter 2022 Financial Results

GlobeNewswire October 27, 2022

DetermaIO(TM) Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer

GlobeNewswire October 6, 2022

Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS

GlobeNewswire September 7, 2022